FREMONT, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that its financial results for the
fourth quarter and year ended December 31, 2004 will be released following the
close of the U.S. financial markets on Monday, March 14, 2005. PDL will hold a
conference call to discuss these results, the status of its clinical
development programs, the status of its pending acquisition of ESP Pharma
Holding Company, Inc. (ESP Pharma) and its forward-looking information and
guidance with respect to future results at 4:30 p.m. Eastern time on March 14,
2005. The call will be hosted by Mr. Mark McDade, Chief Executive Officer,
Mr. Glen Y. Sato, Senior Vice President and Chief Financial Officer, and
Dr. Steven Benner, Senior Vice President and Chief Medical Officer.
PDL noted that the release and conference call had been tentatively
scheduled for February 28, but were rescheduled following the January 25
announcement of PDL's proposed acquisition of ESP Pharma, to allow for
completion of audited financial results for both PDL and ESP Pharma, from
which PDL expects to provide forward-looking guidance for the combined
companies for 2005 based on the assumption that the closing of the proposed
acquisition will be consummated.
The live webcast will be available through the PDL website:
http://www.pdl.com. Please connect to this website at least 15 minutes prior
to the live webcast to allow time for any software download that may be needed
to hear the webcast. Financial and statistical information to be discussed in
the call will be available on the PDL website immediately prior to the
commencement of the call. A replay will be available at http://www.pdl.com
starting approximately one hour after completion of the webcast.
An audio replay will also be available by telephone from approximately
7 p.m. Eastern time on March 14, 2005 through 7 p.m. Eastern time on March 20,
2005. To access the replay, dial 800-633-8284 from inside the United States
and 402-977-9140 from outside the United States; enter conference ID number
21233659.
Protein Design Labs is a leader in the development of humanized antibodies
to prevent or treat various disease conditions. PDL currently has antibodies
under development for autoimmune and inflammatory conditions, asthma and
cancer. PDL holds fundamental patents for its antibody humanization
technology. Further information on PDL is available at http://www.pdl.com or
by contacting James R. Goff, Senior Director, PDL Corporate Communications,
(510) 574-1421 or jgoff@pdl.com.
NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks
of Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
James R. Goff, Senior Director, Corporate
Communications of Protein Design Labs, Inc., +1-510-574-1421, or
jgoff@pdl.com
|
